(αS,3S,5aS,8aS,9aS)-decahydro-9a-hydroxy-3-methyl-1,4-dioxo-α-(2-phenylethyl)-2H-Cyclopenta[4,5]pyrrolo[1,2-a]pyrazine-2-acetic acid, ethyl ester, with CAS number 1309040-96-7, is known as Ramipril EP Impurity L. It is a structurally complex, heterocyclic ester derivative characterized by a fused cyclopenta-pyrrolo-pyrazine ring system. This specific stereoisomer is identified as a process-related impurity or degradation product of the active pharmaceutical ingredient (API) Ramipril. This compound is primarily used as a certified reference standard (CRS) or impurity standard in the pharmaceutical industry. Its main application is in the quality control and analytical testing of Ramipril drug substances and finished dosage forms. It is essential for method development, validation, and routine analysis using techniques like HPLC and LC-MS to monitor and control impurity levels, ensuring the safety, efficacy, and compliance of the cardiovascular drug Ramipril with pharmacopoeial specifications (e.g., European Pharmacopoeia). As a high-purity analytical standard, it is critical for regulatory submissions and maintaining Good Manufacturing Practice (GMP). Handling requires appropriate safety precautions in a controlled laboratory environment.